UK agency Holden Pearmain Research is launching its first US office in New York, to specialise in pharmaceutical research. The company, which was this month placed 48th in the Sunday Times Fast Track 100 list, has also recently launched a qualitative division and opened a third UK office.
Business Development Director, Steve Fleischmann, has been appointed to head up the US launch, and will initially work to develop pharmaceutical research in North America.
Fleischmann has more than 20 years' experience in pharma MR, on both client and agency sides. Most recently, he was VP at @Futures, a research agency specialising in advanced methods and choice modelling. Prior to that, he worked at Triad Research & Consulting and at Market Measures, where he established a consumer research division. He started his career in the Market Analytics department at Pfizer.
The Sunday Times Virgin Atlantic Fast Track 100 is a list of the fastest growing privately owned companies in the UK. Holden Pearman became the second MR agency ever to make the list, thanks to an average 87% annual sales growth between 2001 and 2004.
MD David Holden says the US opening gives the company 'the opportunity to work locally with our US-based pharmaceutical clients, and to allow potential clients to benefit from the research strengths that we currently offer to UK and European clients'.
Holden Pearmain, which specialises in advanced methods, is online at www.holdenpearmain.com.
All articles 2006-19 written and edited by Mel Crowther and/or Nick Thomas.